

RPG – December Q&A

Welcome!

Trusts Represented today include:

Newcastle, Oxford University Hospitals, Northampton, Cambridge, Sussex
and Brighton, Liverpool, Reading, Ayrshire, Lister, North Bristol,
Manchester

Dec – Q&A Themes

- **Supply issues**

- Dalteparin 2,500 units – Lister haven't had supply for 2 weeks, none until, Manchester have pulled stock to renal wards and using the 10,000 units syringes. Issue in Scotland too but procurement weren't aware. Potential for the 10,000 unit syringes supply to stop.
- Tolvapatan – 90mg/30mg Teva brand unavailable. Can double up smaller strength in the meantime (45mg/15mg)

Dec – Q&A Themes

- **Renal**

- Calciphylaxis guideline request shared
- AUC dosing of vancomycin – ASN
- Lokelma – NICE TA 599 – not permitting dialysis use. Some trusts have business cases to use hospital only. SCG for non dialysis use.
- Roxadustat and seizure risk – guideline requirements
- Finenerone – anyone using
- Difelikefalin – anyone using
- Digoxin loading dose in GFR < 30ml/min
- Paxlovid use in GFR < 30ml/min. Wales giving to patients with GFR < 30ml/min but no commissioning currently, Aileen awaiting commissioning statement before changing the monograph. Some references available to support the use. Blueteq needs updating to allow use in GFR < 30ml/min. Also a national shortage of Remdesivir. Evidence to support sotrivimab is poor.
- Cinacalcet crushed via NG for primary hyperparathyroidism – any experience – anecdotally has been safe – to be added to the database as not in any other resources.
- Specific texts used for chemo drug dosing
- Targeted release Budesonide in IgA nephropathy - including recurrence post transplant
- Tolvaptan homecare experience/provider – answers on the chat
- Densoumab in CKD not HD – Cambridge have a consultant on the metabolic bone MDT to advise and will write a protocol and share.
- Bisphosphonates – Manchester avoid using in GFR < 30 ml/min, Oxford also don't use

Dec – Q&A Themes

• RRT

- PD vancomycin dosing for endocarditis
- Amikacin dosing on HD – Manchester had a patient with ototoxicity, did not prescribe NAC.
- Denosumab use in RRT specifically HD patient
- Alternative for unblocking PD catheters given alteplase unavailable
- Amikacin dosing IP on PD – oxford have had two patients and used it IV for this indication. Manchester use oral cipro. Instead. Cambridge taken out of PD peritonitis guideline.
- Roxadustat use on HD patients – funding route IFR or alternative in centre agreement
- Propantheline experience in HD
- IV iron guidelines in CKD/PD/home HD

Nov – Q&A Themes

• Transplant

- Hypercalcaemia management with cinacalcet in transplant population – guideline request
- Belatacept different manufacturer stock – process E stock in supply chain – dose adjustment required
- Roxadustat use in transplant patient – any experience. Aileen has used for patient with a failing kidney, EPO resistant patient.
- MMF dosing post ATG in new transplant patient
- Harvesting and freezing of eggs / immunosuppression adjustment for MMF patient planning pregnancy. ?don't need to stop it.
- TB treatment / rifampicin use in tacrolimus patient
- rATG for rejection – course length given rATG use at induction
- Experience in measuring free (unbound) tacrolimus levels
- Equine ATG guidelines
- Equine ATG vs Rabbit ATG. Equine is much less efficacious but is used in haematology.
- Washout time required for stopping allopurinol and starting azathioprine. No not required but should not be sued together.

Updates

- Membranous GN - NHSE Commissioning
 - <https://www.england.nhs.uk/publication/clinical-commissioning-policy-rituximab-for-idiopathic-membranous-nephropathy/>
 - Blueteq form not available yet.
- EMPA KIDNEY
 - <https://www.nejm.org/doi/full/10.1056/NEJMoa2204233>
 - Presentation at Oxford, to be used at lower GFR and lower protein urea levels.
- STOP ACE
 - <https://www.nejm.org/doi/pdf/10.1056/NEJMoa2210639>
 - Presentation with UKKA 15/12/2022 – register!!
- Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis
 - Technology appraisal guidance [TA825] Published: 21 September 2022

2023 – On the Horizon

- Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]
 - In development [GID-TA10820] Expected publication date: 22 March 2023
- Difelikefalin for treating pruritus in people having haemodialysis [ID3890]
 - In development [GID-TA10793] Expected publication date: 26 April 2023
- Voclosporin with immunosuppressives for treating lupus nephritis [ID3962]
 - In development [GID-TA10878] Expected publication date: 26 April 2023

Dec Q&A: New Q

- Metolazone – guidance around the bioavailability statement is not accurate, halving the dose may be unnecessary. RPG statement being written, need to take into account that changing the dose may not change the efficacy. Liverpool have not released guidance but taking as case by case basis.
- UKKA statement released today!

Dec Q&A: New Q

- Cardio-renal forum in January to be shared on the whatsapp group, how to manage heart failure patients with renal failure. Free Webinar to join.

Dec Q&A: New Q



Dec Q&A: New Q



Dec Q&A: New Q



Dec Q&A: New Q



Dec Q&A: New Q



Dec Q&A: New Q



Dec Q&A: New Q



Dec Q&A - Close

REMINDER: WhatsApp Q&A platform – 60+ participants; Very useful real time forum for clinical Q's – please consider joining.

Thank you for attending.

See you in 2023!!

Next Q&A: January 10th @ 1pm